150 related articles for article (PubMed ID: 17324336)
41. FcgammaRIIA, FcgammaRIIIA and FcgammaRIIIB polymorphisms in Spanish patients with systemic lupus erythematosus.
González-Escribano MF; Aguilar F; Sánchez-Román J; Núñez-Roldán A
Eur J Immunogenet; 2002 Aug; 29(4):301-6. PubMed ID: 12121275
[TBL] [Abstract][Full Text] [Related]
42. Association between Fcγ receptor IIA, IIIA and IIIB genetic polymorphisms and susceptibility to severe malaria anemia in children in western Kenya.
Munde EO; Okeyo WA; Raballah E; Anyona SB; Were T; Ong'echa JM; Perkins DJ; Ouma C
BMC Infect Dis; 2017 Apr; 17(1):289. PubMed ID: 28427365
[TBL] [Abstract][Full Text] [Related]
43. Development of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodies.
Tada M; Ishii-Watabe A; Suzuki T; Kawasaki N
PLoS One; 2014; 9(4):e95787. PubMed ID: 24752341
[TBL] [Abstract][Full Text] [Related]
44. Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.
Cuello HA; Segatori VI; Alberto M; Pesce A; Alonso DF; Gabri MR
BioDrugs; 2016 Jun; 30(3):225-31. PubMed ID: 27053342
[TBL] [Abstract][Full Text] [Related]
45. Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy.
Cornec D; Tempescul A; Querellou S; Hutin P; Pers JO; Jamin C; Bendaoud B; Berthou C; Renaudineau Y; Youinou P
Ann Hematol; 2012 May; 91(5):715-721. PubMed ID: 22083514
[TBL] [Abstract][Full Text] [Related]
46. Impact of Fc receptors and host characteristics on myeloid phagocytic response to rituximab-treated 3D-cultured B-cell lymphoma.
Kleinau S
Immunother Adv; 2023; 3(1):ltad025. PubMed ID: 38020313
[TBL] [Abstract][Full Text] [Related]
47. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
Musolino A; Naldi N; Bortesi B; Pezzuolo D; Capelletti M; Missale G; Laccabue D; Zerbini A; Camisa R; Bisagni G; Neri TM; Ardizzoni A
J Clin Oncol; 2008 Apr; 26(11):1789-96. PubMed ID: 18347005
[TBL] [Abstract][Full Text] [Related]
48. [Influence of FcγRIIIa polymorphism on rituximab-dependent NK cell-mediated cytotoxicity to Raji cells].
Qu YH; Li Y; Wu YF; Fang JP; Huang SL; Huang Y; Wei J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1269-74. PubMed ID: 21129274
[TBL] [Abstract][Full Text] [Related]
49. FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma.
Fabisiewicz A; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Siedlecki JA
Leuk Lymphoma; 2011 Aug; 52(8):1604-6. PubMed ID: 21657954
[No Abstract] [Full Text] [Related]
50. The impact of
Rožman S; Novaković S; Grabnar I; Cerkovnik P; Novaković BJ
Oncol Lett; 2016 May; 11(5):3332-3336. PubMed ID: 27123112
[TBL] [Abstract][Full Text] [Related]
51. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
[TBL] [Abstract][Full Text] [Related]
52. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma.
Forero-Torres A; de Vos S; Pohlman BL; Pashkevich M; Cronier DM; Dang NH; Carpenter SP; Allan BW; Nelson JG; Slapak CA; Smith MR; Link BK; Wooldridge JE; Ganjoo KN
Clin Cancer Res; 2012 Mar; 18(5):1395-403. PubMed ID: 22223529
[TBL] [Abstract][Full Text] [Related]
53. Fc gamma receptor glycosylation modulates the binding of IgG glycoforms: a requirement for stable antibody interactions.
Hayes JM; Frostell A; Cosgrave EF; Struwe WB; Potter O; Davey GP; Karlsson R; Anneren C; Rudd PM
J Proteome Res; 2014 Dec; 13(12):5471-85. PubMed ID: 25345863
[TBL] [Abstract][Full Text] [Related]
54. Association of the Fc gamma receptor IIA-R/R131 genotype with myasthenia gravis in Dutch patients.
van der Pol WL; Jansen MD; Kuks JB; de Baets M; Leppers-van de Straat FG; Wokke JH; van de Winkel JG; van den Berg LH
J Neuroimmunol; 2003 Nov; 144(1-2):143-7. PubMed ID: 14597109
[TBL] [Abstract][Full Text] [Related]
55. Fcgamma receptor polymorphisms in populations in Ethiopia and Norway.
Van Den Berg L; Myhr KM; Kluge B; Vedeler CA
Immunology; 2001 Sep; 104(1):87-91. PubMed ID: 11576225
[TBL] [Abstract][Full Text] [Related]
56. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
Dall'Ozzo S; Tartas S; Paintaud G; Cartron G; Colombat P; Bardos P; Watier H; Thibault G
Cancer Res; 2004 Jul; 64(13):4664-9. PubMed ID: 15231679
[TBL] [Abstract][Full Text] [Related]
57. Platelet FcgammaRIIA His131Arg polymorphism and platelet function: antibodies to platelet-bound fibrinogen induce platelet activation.
Chen J; Dong JF; Sun C; Bergeron A; McBride L; Pillai M; Barnard MR; Salmon J; Michelson AD; Bray PF
J Thromb Haemost; 2003 Feb; 1(2):355-62. PubMed ID: 12871511
[TBL] [Abstract][Full Text] [Related]
58. CD64 surface expression on neutrophils and monocytes is significantly up-regulated after stimulation with granulocyte colony-stimulating factor during CHOP chemotherapy for patients with non-Hodgkin's lymphoma.
Kakinoki Y; Kubota H; Yamamoto Y
Int J Hematol; 2004 Jan; 79(1):55-62. PubMed ID: 14979480
[TBL] [Abstract][Full Text] [Related]
59. The rs150311303 polymorphism in FcγRIIa enhances IgG binding capacity.
Omar AH; Shibata H; Yasunami M; Yamazaki A; Ofori MF; Akanmori BD; Shuaibu MN; Kikuchi M; Hirayama K
Scand J Immunol; 2012 Aug; 76(2):167-74. PubMed ID: 22540264
[TBL] [Abstract][Full Text] [Related]
60. Rituximab immunotherapy for non-Hodgkin's lymphoma.
White CA
Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
